Developer docs
API playgroundTry for free, no card

Search company profiles

AULBIO

Full company profile

uuid0003hpx

Namestring
AULBIO
Legal namestring
AULBIO Co., Ltd.
Websiteurl
aulbio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

AULBIO Co., Ltd. is a South Korean biotechnology company founded in 2018 and headquartered in Seongnam, Gyeonggi-do, that develops long-acting injectable (LAI) drug-delivery formulations for peptide therapeutics. Its proprietary ExTenna™ platform is a third-generation hybrid microsphere technology combining microfluidic processing with solvent-free PLGA encapsulation, enabling high drug loading and once-monthly administration of peptide active ingredients while maintaining sustained plasma exposure and improved patient adherence versus conventional delivery systems. The company maintains a GMP production plant in Chuncheon, Gangwon-do, alongside an R&D institute in Seongnam, forming an integrated smart manufacturing system designed for large-scale, uniform microsphere production.

The company operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), generating revenue through co-development agreements, technology licensing, and GMP manufacturing services for pharmaceutical partners. Its customer base is concentrated in pharmaceutical enterprises seeking advanced drug-delivery solutions in obesity and metabolic disease, with named disclosed partners including KyungDong Pharmaceutical (Co., Ltd.) for a semaglutide-based once-monthly injectable and a Nasdaq-listed US biopharmaceutical company for a once-monthly next-generation GLP-1 receptor agonist program. Distribution is conducted through direct enterprise engagement rather than product channels, supplemented by participation in industry partnering events such as the BIO International Convention via Korea's KHIDI Project NOVA open-innovation initiative.

AULBIO is privately held, founder-controlled (co-founded by Dr. Cherng-Ju Kim and Dr. Taekun An), and is preparing for a KOSDAQ listing targeted for 2027 with KB Securities as lead underwriter, following an October 2025 leadership restructuring that elevated Dr. Kim to CEO and assigned Dr. An to a CSO role focused on corporate strategy, partnerships, and commercialization. Cumulative disclosed equity funding to date totals approximately $5.7M across Series 1 and Series 2 rounds between 2019 and 2022.

Short descriptiontext

AULBIO (Seongnam, South Korea) is a 2018-founded CRDMO that develops long-acting injectable peptide therapeutics using its proprietary ExTenna™ hybrid microsphere and solvent-free PLGA platform, serving global and Korean pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
long-acting injectables, microsphere drug delivery, contract biopharmaceutical manufacturing, peptide sustained release, PLGA microsphere CRDMO
Industry1 code
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Contract Biopharmaceutical Manufacturing (CRDMO) for Long-Acting Injectables
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Co-development and Contract Research Services
TypeProfessional Services
Description

AULBIO generates revenue through co-development agreements with pharmaceutical partners, providing formulation development and manufacturing services for long-acting injectable therapeutics based on its ExTenna™ platform.

aulbio.com
2Technology Licensing and Transfer
TypeLicensing Royalties
Description

The company earns revenue through technology-transfer collaborations with global and Korean pharmaceutical companies, licensing its proprietary microsphere drug delivery platform for partner drug candidates.

aulbio.com
3CRDMO Services
TypeManaged Services
Description

Contract research, development, and manufacturing organization services offering end-to-end support from formulation development through GMP production of long-acting injectable products.

aulbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

AULBIO develops and operates a proprietary ExTenna™ microfluidic-based long-acting injectable (LAI) drug delivery platform built on solvent-free PLGA microsphere technology. The company operates as a CRDMO, providing formulation development, technology transfer, and GMP manufacturing services for peptide-based long-acting injectables such as once-monthly GLP-1 receptor agonists and semaglutide formulations, in collaboration with global and Korean pharmaceutical partners. Its offering combines proprietary platform IP, a capital-intensive Smart Manufacturing System, and co-development partnerships to convert partner drug candidates into long-acting therapeutics with improved patient adherence.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Once-monthly sustained plasma exposure demonstrated through co-development of GLP-1 RA program with Nasdaq-listed US biopharma partner.
+1 more record
Product overview1 text field

AULBIO is a biotechnology company specializing in microfluidic-based long-acting injectable (LAI) formulations. The company's core offering is the Extenna platform, a third-generation hybrid microsphere drug delivery technology that enables high-load encapsulation of therapeutic agents within ultra-fine microspheres for sustained plasma exposure and improved patient adherence. AULBIO operates as a CRDMO (Contract Research, Development, and Manufacturing Organization), offering its platform technology and smart manufacturing infrastructure to transform partners' drug candidates into world-class long-acting therapeutics. The current pipeline includes GLP-1 receptor agonist programs for obesity treatment and semaglutide-based formulations, developed through partnerships with US-listed biopharmaceutical companies and KyungDong Pharmaceutical.

Product and service5 records
1ExTenna™ Microsphere Drug Delivery Platform
CategoryDrug Delivery Platform Technology
Description

Proprietary third-generation hybrid PLGA microsphere drug delivery platform enabling high-load encapsulation of therapeutic agents within ultra-fine, highly uniform microspheres for long-acting injectable formulations; licensed to pharmaceutical partners and used as the foundation of AULBIO's CRDMO and co-development offerings.

2CRDMO Services (Contract Research, Development & Manufacturing)
CategoryContract Biopharmaceutical Manufacturing
Description

Contract Research, Development, and Manufacturing Organization services that transform partners' drug candidates into long-acting therapeutics using the ExTenna platform, covering formulation development, technology transfer, and GMP production; targeted at pharmaceutical and biopharmaceutical partners seeking LAI formulation capabilities.

3Smart Manufacturing System
CategoryContract Biopharmaceutical Manufacturing
Description

Capital-intensive GMP-grade manufacturing infrastructure at AULBIO's Chuncheon production plant that enables large-scale, uniform production of microspheres and is offered as part of the company's CRDMO service to partners.

4Once-Monthly GLP-1 RA Injectable Program
CategoryLong-Acting Injectable Pipeline Program
Description

Co-developed once-monthly long-acting injectable program based on a next-generation GLP-1 receptor agonist peptide analog, enabled by AULBIO's solvent-free PLGA microsphere platform and targeted at obesity and metabolic disease.

5Semaglutide Long-Acting Injectable Program
CategoryLong-Acting Injectable Pipeline Program
Description

Semaglutide-based once-monthly long-acting injectable formulation co-developed with KyungDong Pharmaceutical using the ExTenna microsphere platform.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

AULBIO participated in KHIDI-organized one-on-one partnering sessions between Korean biotechnology firms and AstraZeneca experts at the BIO International Convention in San Diego under Project NOVA. The initiative is part of Korea's open innovation strategy and K-Biopharma Next Bridge initiative launched with Korea's Ministry of Health and Welfare.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

AULBIO is working closely with KyungDong Pharmaceutical to advance the development of a semaglutide-based long-acting injectable therapy at an accelerated pace. This partnership leverages AULBIO's ExTenna™ microsphere platform for formulation development.

3Nasdaq-listed US biopharmaceutical company
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-14
Description

AULBIO entered into a co-development agreement with a US-listed biopharmaceutical company to advance a next-generation GLP-1 receptor agonist (RA) program designed for once-monthly administration. The collaboration integrates AULBIO's solvent-free PLGA microsphere platform with the partner's innovative peptide analog, achieving sustained plasma exposure for obesity and metabolic disease treatment. This represents AULBIO's first global co-development milestone.

aulbio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish specialty pharma with the FluidCrystal® injectable depot platform for sustained-release peptides and small molecules. A leader in long-acting injectables and directly comparable technology/market overlap with AULBIO.

2Forbon Pharma
TypeDirect peer
Description

China-based PLGA microsphere drug delivery and CRDMO specialist serving peptide and small-molecule partners. Most directly comparable Chinese peer to AULBIO's ExTenna™ PLGA microsphere CRDMO business.

TypeEmerging player
Description

Ireland/US specialty pharma built around extended-release/once-nightly injectable technologies. Comparable emerging player pursuing reduced dosing frequency as a market wedge, similar to AULBIO's once-monthly positioning.

TypeBroad incumbent
Description

Ireland/US-based LAI specialist with approved products (Vivitrol, Aristada) and proprietary polymer-based depot technology plus inhaled drug delivery. Established global incumbent in long-acting injectables whose technology and CRDMO-like partnerships map closely onto AULBIO's ambitions.

TypeDirect peer
Description

Dutch microsphere/PLGA-based LAI formulation specialist offering contract development and GMP manufacturing services to pharma partners. Directly comparable to AULBIO's ExTenna™ platform and CRDMO model for long-acting injectable peptides.

TypeBroad incumbent
Description

Global CDMO offering formulation development and GMP manufacturing for complex injectables including sustained-release/sterile products. Comparable as a broad contract development and manufacturing incumbent competing for the same LAI partner work AULBIO pursues.

TypeDirect peer
Description

US specialty pharma operating Eligard (leuprolide acetate LAI for prostate cancer) with proprietary ATRIGEL® and other polymer depot delivery systems. Closely comparable LAI platform company with similar peptide-depot use cases to AULBIO's obesity/semaglutide pipeline.

TypeBroad incumbent
Description

German specialty chemicals leader with the RESOMER® portfolio of PLGA polymers used in microsphere LAIs and GMP manufacturing services. Comparable as an enabling technology/contract manufacturing incumbent in the PLGA long-acting injectable supply chain.

TypeDirect peer
Description

China-headquartered pharma with a long-acting injectable technology platform (microspheres/liposomes) and global partnerships. A directly comparable LAI specialist operating in a similar Asia-anchored CRDMO/co-development model.

TypeBroad incumbent
Description

French specialty pharma with multiple long-acting injectable franchises (e.g., Somatuline, Decapeptyl) and established LAI manufacturing capability. A global incumbent comparable on LAI platform use cases and partner supply models.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AULBIO

Contract Biopharmaceutical Manufacturing (CRDMO) for Long-Acting Injectablesaulbio.com

AULBIO (Seongnam, South Korea) is a 2018-founded CRDMO that develops long-acting injectable peptide therapeutics using its proprietary ExTenna™ hybrid microsphere and solvent-free PLGA platform, serving global and Korean pharmaceutical partners.

What AULBIO does

AULBIO Co., Ltd. is a South Korean biotechnology company founded in 2018 and headquartered in Seongnam, Gyeonggi-do, that develops long-acting injectable (LAI) drug-delivery formulations for peptide therapeutics. Its proprietary ExTenna™ platform is a third-generation hybrid microsphere technology combining microfluidic processing with solvent-free PLGA encapsulation, enabling high drug loading and once-monthly administration of peptide active ingredients while maintaining sustained plasma exposure and improved patient adherence versus conventional delivery systems. The company maintains a GMP production plant in Chuncheon, Gangwon-do, alongside an R&D institute in Seongnam, forming an integrated smart manufacturing system designed for large-scale, uniform microsphere production.

The company operates as a Contract Research, Development, and Manufacturing Organization (CRDMO), generating revenue through co-development agreements, technology licensing, and GMP manufacturing services for pharmaceutical partners. Its customer base is concentrated in pharmaceutical enterprises seeking advanced drug-delivery solutions in obesity and metabolic disease, with named disclosed partners including KyungDong Pharmaceutical (Co., Ltd.) for a semaglutide-based once-monthly injectable and a Nasdaq-listed US biopharmaceutical company for a once-monthly next-generation GLP-1 receptor agonist program. Distribution is conducted through direct enterprise engagement rather than product channels, supplemented by participation in industry partnering events such as the BIO International Convention via Korea's KHIDI Project NOVA open-innovation initiative.

AULBIO is privately held, founder-controlled (co-founded by Dr. Cherng-Ju Kim and Dr. Taekun An), and is preparing for a KOSDAQ listing targeted for 2027 with KB Securities as lead underwriter, following an October 2025 leadership restructuring that elevated Dr. Kim to CEO and assigned Dr. An to a CSO role focused on corporate strategy, partnerships, and commercialization. Cumulative disclosed equity funding to date totals approximately $5.7M across Series 1 and Series 2 rounds between 2019 and 2022.

AULBIO firmographics

Firmographics
Name
AULBIO
Legal name
AULBIO Co., Ltd.
Website
https://aulbio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
AULBIO (Seongnam, South Korea) is a 2018-founded CRDMO that develops long-acting injectable peptide therapeutics using its proprietary ExTenna™ hybrid microsphere and solvent-free PLGA platform, serving global and Korean pharmaceutical partners.
Ownership category
akta.pro rank

AULBIO industry classification

Industry
Product category
Contract Biopharmaceutical Manufacturing (CRDMO) for Long-Acting Injectables
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Long-acting injectables
  • Microsphere drug delivery
  • Contract biopharmaceutical manufacturing
  • Peptide sustained release
  • PLGA microsphere CRDMO

Where AULBIO is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

AULBIO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Co-development and Contract Research Services: AULBIO generates revenue through co-development agreements with pharmaceutical partners, providing formulation development and manufacturing services for long-acting injectable therapeutics based on its ExTenna™ platform.
  2. Technology Licensing and Transfer: The company earns revenue through technology-transfer collaborations with global and Korean pharmaceutical companies, licensing its proprietary microsphere drug delivery platform for partner drug candidates.
  3. CRDMO Services: Contract research, development, and manufacturing organization services offering end-to-end support from formulation development through GMP production of long-acting injectable products.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

AULBIO product offering

Product offering

Core offering

AULBIO develops and operates a proprietary ExTenna™ microfluidic-based long-acting injectable (LAI) drug delivery platform built on solvent-free PLGA microsphere technology. The company operates as a CRDMO, providing formulation development, technology transfer, and GMP manufacturing services for peptide-based long-acting injectables such as once-monthly GLP-1 receptor agonists and semaglutide formulations, in collaboration with global and Korean pharmaceutical partners. Its offering combines proprietary platform IP, a capital-intensive Smart Manufacturing System, and co-development partnerships to convert partner drug candidates into long-acting therapeutics with improved patient adherence.

Product overview

AULBIO is a biotechnology company specializing in microfluidic-based long-acting injectable (LAI) formulations. The company's core offering is the Extenna platform, a third-generation hybrid microsphere drug delivery technology that enables high-load encapsulation of therapeutic agents within ultra-fine microspheres for sustained plasma exposure and improved patient adherence. AULBIO operates as a CRDMO (Contract Research, Development, and Manufacturing Organization), offering its platform technology and smart manufacturing infrastructure to transform partners' drug candidates into world-class long-acting therapeutics. The current pipeline includes GLP-1 receptor agonist programs for obesity treatment and semaglutide-based formulations, developed through partnerships with US-listed biopharmaceutical companies and KyungDong Pharmaceutical.

Differentiator

Problem solved

Functional benefit

Products and services

  • ExTenna™ Microsphere Drug Delivery Platform Proprietary third-generation hybrid PLGA microsphere drug delivery platform enabling high-load encapsulation of therapeutic agents within ultra-fine, highly uniform microspheres for long-acting injectable formulations; licensed to pharmaceutical partners and used as the foundation of AULBIO's CRDMO and co-development offerings.
  • CRDMO Services (Contract Research, Development & Manufacturing) Contract Research, Development, and Manufacturing Organization services that transform partners' drug candidates into long-acting therapeutics using the ExTenna platform, covering formulation development, technology transfer, and GMP production; targeted at pharmaceutical and biopharmaceutical partners seeking LAI formulation capabilities.
  • Smart Manufacturing System Capital-intensive GMP-grade manufacturing infrastructure at AULBIO's Chuncheon production plant that enables large-scale, uniform production of microspheres and is offered as part of the company's CRDMO service to partners.
  • Once-Monthly GLP-1 RA Injectable Program Co-developed once-monthly long-acting injectable program based on a next-generation GLP-1 receptor agonist peptide analog, enabled by AULBIO's solvent-free PLGA microsphere platform and targeted at obesity and metabolic disease.
  • Semaglutide Long-Acting Injectable Program Semaglutide-based once-monthly long-acting injectable formulation co-developed with KyungDong Pharmaceutical using the ExTenna microsphere platform.

Quantifiable outcome

  • Once-monthly sustained plasma exposure demonstrated through co-development of GLP-1 RA program with Nasdaq-listed US biopharma partner.
  • +1 more outcomes

Companies that use AULBIO

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

AULBIO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

AULBIO partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered supporting and core.

  • KHIDI / Project NOVAsupportingStrategic or Co-development Partner · 23 June 2026AULBIO participated in KHIDI-organized one-on-one partnering sessions between Korean biotechnology firms and AstraZeneca experts at the BIO International Convention in San Diego under Project NOVA. The initiative is part of Korea's open innovation strategy and K-Biopharma Next Bridge initiative launched with Korea's Ministry of Health and Welfare.
  • KyungDong Pharmaceutical (경동제약)coreStrategic or Co-development Partner · 27 October 2025AULBIO is working closely with KyungDong Pharmaceutical to advance the development of a semaglutide-based long-acting injectable therapy at an accelerated pace. This partnership leverages AULBIO's ExTenna™ microsphere platform for formulation development.
  • Nasdaq-listed US biopharmaceutical companycoreStrategic or Co-development Partner · 14 February 2025AULBIO entered into a co-development agreement with a US-listed biopharmaceutical company to advance a next-generation GLP-1 receptor agonist (RA) program designed for once-monthly administration. The collaboration integrates AULBIO's solvent-free PLGA microsphere platform with the partner's innovative peptide analog, achieving sustained plasma exposure for obesity and metabolic disease treatment. This represents AULBIO's first global co-development milestone.

Scale indicators2 records

Recent moves7 records

Expansion highlights5 records

AULBIO competitors and assessment

Company assessment

Direct peers

  • Camurus: Swedish specialty pharma with the FluidCrystal® injectable depot platform for sustained-release peptides and small molecules. A leader in long-acting injectables and directly comparable technology/market overlap with AULBIO.
  • Forbon Pharma: China-based PLGA microsphere drug delivery and CRDMO specialist serving peptide and small-molecule partners. Most directly comparable Chinese peer to AULBIO's ExTenna™ PLGA microsphere CRDMO business.
  • Nanomi: Dutch microsphere/PLGA-based LAI formulation specialist offering contract development and GMP manufacturing services to pharma partners. Directly comparable to AULBIO's ExTenna™ platform and CRDMO model for long-acting injectable peptides.
  • Tolmar Pharmaceuticals: US specialty pharma operating Eligard (leuprolide acetate LAI for prostate cancer) with proprietary ATRIGEL® and other polymer depot delivery systems. Closely comparable LAI platform company with similar peptide-depot use cases to AULBIO's obesity/semaglutide pipeline.
  • Luye Pharma Group: China-headquartered pharma with a long-acting injectable technology platform (microspheres/liposomes) and global partnerships. A directly comparable LAI specialist operating in a similar Asia-anchored CRDMO/co-development model.

Emerging players

  • Avadel Pharmaceuticals: Ireland/US specialty pharma built around extended-release/once-nightly injectable technologies. Comparable emerging player pursuing reduced dosing frequency as a market wedge, similar to AULBIO's once-monthly positioning.

Broad incumbents

  • Alkermes: Ireland/US-based LAI specialist with approved products (Vivitrol, Aristada) and proprietary polymer-based depot technology plus inhaled drug delivery. Established global incumbent in long-acting injectables whose technology and CRDMO-like partnerships map closely onto AULBIO's ambitions.
  • Catalent: Global CDMO offering formulation development and GMP manufacturing for complex injectables including sustained-release/sterile products. Comparable as a broad contract development and manufacturing incumbent competing for the same LAI partner work AULBIO pursues.
  • Evonik Health Care: German specialty chemicals leader with the RESOMER® portfolio of PLGA polymers used in microsphere LAIs and GMP manufacturing services. Comparable as an enabling technology/contract manufacturing incumbent in the PLGA long-acting injectable supply chain.
  • Ipsen: French specialty pharma with multiple long-acting injectable franchises (e.g., Somatuline, Decapeptyl) and established LAI manufacturing capability. A global incumbent comparable on LAI platform use cases and partner supply models.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

AULBIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AULBIO leadership team

Management profile

Number of profiles

Profiles2 records

AULBIO funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AULBIO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AULBIO

What does AULBIO do?

AULBIO develops and operates a proprietary ExTenna™ microfluidic-based long-acting injectable (LAI) drug delivery platform built on solvent-free PLGA microsphere technology. The company operates as a CRDMO, providing formulation development, technology transfer, and GMP manufacturing services for peptide-based long-acting injectables such as once-monthly GLP-1 receptor agonists and semaglutide formulations, in collaboration with global and Korean pharmaceutical partners. Its offering combines proprietary platform IP, a capital-intensive Smart Manufacturing System, and co-development partnerships to convert partner drug candidates into long-acting therapeutics with improved patient adherence.

Is AULBIO a public or private company?

AULBIO is a private company. It is classified as venture growth investor backed and is currently operating.

When was AULBIO founded?

AULBIO was founded in 2018. It employs 1 to 10 people.

Where is AULBIO based?

AULBIO is headquartered in Seongnam, South Korea, in the Asia region.

How does AULBIO make money?

Three revenue lines are on record. Co-development and Contract Research Services are the primary driver. The others are technology Licensing and Transfer and CRDMO Services.

Who are AULBIO's main competitors?

Direct peers on record are Camurus, Forbon Pharma, Nanomi, Tolmar Pharmaceuticals and Luye Pharma Group. Avadel Pharmaceuticals is listed as an emerging player. Broad incumbents are Alkermes, Catalent, Evonik Health Care and Ipsen.

Does AULBIO have an API?

No public API is recorded for AULBIO.

What industry is AULBIO in?

AULBIO's product category is Contract Biopharmaceutical Manufacturing (CRDMO) for Long-Acting Injectables. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales